Abstract
Dorsal hippocampus is one of the brain regions which plays an important role in anxiety. In the present study we investigated the effects of Intra-dorsal hippocampus (CA1) microinjection of NMDA-glutamatergic receptor agonist, NMDA and its antagonist, MK-801 on anxiety-related behavior in rats. Elevated plus-maze (EPM) which is one of the common methods employed for testing of anxiety was used in this study. Rats were anaesthetized with a mixture of ketamine and xylazine and special cannulas were inserted stereotaxically into the CA1 region of the dorsal hippocampus. After a one-week recovery, the effects of intra-CA1 administration of NMDA receptor agents were studied. Bilateral Intra-dorsal hippocampus microinjection of different doses of NMDA (0.25, 0.5, 0.75 and 1 μg/rat) increased the percentage of open arm time (%OAT) and open arm entries (%OAE), indicating an anxiolytic-like behavior. On the other hand, administration of MK-801 (60, 125, 250 and 500 ng/rat) decreased %OAT and %OAE significantly. Pre-treatment administration of MK-801(60, 125, 250 and 500 ng/rat) reversed the anxiolytic effect of NMDA (0.5 μg/rat) microinjection into the dorsal hippocampus in a dose-dependent manner. From the findings of the present study, it can be concluded that the NMDA-glutamatergic system in the dorsal hippocampus is involved in anxiety-related behaviors.
Similar content being viewed by others
Abbreviations
- EPM:
-
Elevated plus-maze
- CA1:
-
Dorsal hippocampus
- %OAT:
-
Percentage of open arm time
- %OAE:
-
Percentage open arm entries
- NMDA:
-
N-methyl-d-aspartate
- CNS:
-
Central nervous system
- GABA:
-
Γ-aminobutyric acid
- MK 801:
-
MK-801 hydrogen maleate
References
Kessler, R., Chiu, W., Demler, O., and Walters, E., Arch. Gen. Psychiatry, 2005, vol. 62, p. 617.
Greenberg, P., Sisitsky, T., Kessler, R., Finkelstein, S., Berndt, E., Davidson, J., Ballenger, J., and Fyer, A., J. Clin. Psychiatry, 1999, vol. 60, pp. 427–435.
Bergink, V., van Megen, and Westenberg, H., Eur. Neuropsychopharmacol., 2004, vol. 14, pp. 175–183.
File, S., Kenny, P., and Cheeta, S., Pharmacol. Biochem. Behav., 2000, vol. 66, pp. 65–72.
Graeff, F., Guimaraes, F., De Andrade, T., and Deakin, J., Pharmacol. Biochem. Behav., 1996, vol. 54, pp. 129–141.
Engin, E. and Treit, D., Behav. Pharmacol., 2007, vol. 18, p. 365.
File, S., Gonzalez, L., and Andrews, N., Behav. Neurosci., 1998, vol. 112, p. 352.
Clement, Y. and Chapouthier, G., Neurosci. Biobehav. Rev., 1998, vol. 22, pp. 623–633.
Kew, J. and Kemp, J., Psychopharmacol., 2005, vol. 179, pp. 4–29.
Guimarães, F., Carobrez, A., Aguiar, J., and Graeff, F., Psychopharmacol., 1991, vol. 103, pp. 91–94.
Tsai, M., PhD, G., and Coyle, M., Ann. Rev. Med., 1998, vol. 49, pp. 173–184.
Amiel, J. and Mathew, S., Cur. Psychiatry, 2007, vol. 9, pp. 278–283.
Greenamyre, J. and Porter, R., Neurol., 1994, vol. 44, pp. 7–13.
Palucha, A., Tatarczynska, E., Branski, P., Szewczyk, B., Wieronska, J., Klak, K., Chojnacka-Wojcik, E., Nowak, G., and Pilc, A., Neuropharmacol., 2004, vol. 46, pp. 151–159.
Cortese, B. and Phan, K., CNS Spectrums, 2005, vol. 10, p. 820.
Paxinos, G., The Rat Brain in Stereotaxic Coordinates, San Diego: Elsevier Academic Press, 2007.
Degroot, A., Kashluba, S., and Treit, D., Pharmacol. Biochem. and Behav., 2001, vol. 69, pp. 391–399.
Pellow, S., Chopin, P., File, S.E., and Briley, M., J. Neurosci. Meth., 1985, vol. 14, pp. 149–167.
Pellow, S., Methods. Find. Exp. Clin. Pharmacol., 1986, vol. 8, pp. 557–565.
Zarrindast, M., Solati, J., Oryan, S., and Parivar, K., Pharmacol., 2008, vol. 82, pp. 276–284.
Solati, J., Zarrindast, M., and Salari, A., Psychiatry Clin. Neurosci., 2010, vol. 64, pp. 634–641.
File, S., Kenny, P., and Cheeta, S., Pharmacol. Biochem. Behav., 2000, vol. 66, pp. 65–72.
Willetts, J., Clissold, D., Hartman, T., Brandsgaard, R., Hamilton, G., and Ferkany, J., J. Pharmacol. Exp. Ther., 1993, vol. 265, pp. 1055–1062.
Linden, A., Shannon, H., Baez, M., Yu, J., Koester, A., and Schoepp, D., Psychopharmacol., 2005, vol. 179, pp. 284–291.
Tatarczynska, E., Klodzinska, A., Kroczka, B., Chojnacka-Wójcik, E., and Pilc, A., Psychopharmacol., 2001, vol. 158, pp. 94–99.
Wong, E., Knight, A., and Woodruff, G., J. Neurochem., 1988, vol. 50, pp. 274–281.
Jardim, M. and Guimaraes, F., Pharmacol. Biochem. Behav., 2004, vol. 79, pp. 541–546.
Stephens, D., Meldrum, B., Weidmann, R., Schneider, C., and Grützner, M., Psychopharmacol., 1986, vol. 90, pp. 166–169.
Author information
Authors and Affiliations
Corresponding author
Additional information
The article is published in the original.
Rights and permissions
About this article
Cite this article
Solati, J., Salari, A.A. Involvement of dorsal hippocampal NMDA-glutamatergic system in anxiety-related behaviors of rats. Neurochem. J. 5, 194–199 (2011). https://doi.org/10.1134/S1819712411030081
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1819712411030081